Context Therapeutics (CNTX) Cash from Investing Activities (2021 - 2026)
Context Therapeutics (CNTX) posted Cash from Investing Activities of -$37258.0 for Q1 2026, up 98.14% sequentially from -$2.0 million in Q4 2025, and down 9.75% YoY from -$41283.2 in Q1 2025.
Context Therapeutics (CNTX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Context Therapeutics has reported Cash from Investing Activities for 5 years, with the latest figure at -$37258.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 9.75% year-over-year to -$37258.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (up 86.23% YoY) and the FY2025 annual result came in at -$2.0 million, up 86.22% from the prior year.
- Cash from Investing Activities advanced to -$37258.0 in Q1 2026 per CNTX's latest filing, from -$2.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$1837.0 in Q2 2022 and troughed at -$14.8 million in Q3 2024.
- A 4-year average of -$2.5 million and a median of -$37258.0 in 2026 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities soared 99.27% in 2022, then slipped 9.75% in 2026.
- Over 4 years, Cash from Investing Activities stood at -$500000.0 in 2022, then sank by 2851.46% to -$14.8 million in 2024, then soared by 86.45% to -$2.0 million in 2025, then soared by 98.14% to -$37258.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$37258.0, -$2.0 million, and -$33948.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -4.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.52 Mn |
| Jun 30, 2026 | -4.52 Mn |
| Mar 31, 2026 | -37,258.00 |
| Mar 31, 2026 | -37,258.00 |
| Dec 31, 2025 | -2.00 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -33,948.00 |
| Mar 31, 2025 | -33,948.00 |
| Sep 30, 2024 | -14.76 Mn |
| Sep 30, 2024 | -14.76 Mn |
| Sep 30, 2022 | -500,000.00 |
| Sep 30, 2022 | -500,000.00 |
| Jun 30, 2022 | -1,837.00 |
| Jun 30, 2022 | -1,837.00 |
| Mar 31, 2022 | -34,999.00 |
| Mar 31, 2022 | -34,999.00 |
| Jun 30, 2021 | -250,000.00 |
| Jun 30, 2021 | -250,000.00 |